Results 51 to 60 of about 999 (177)

Cardiac magnetic resonance left atrioventricular coupling index as a prognostic tool in hypertrophic cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Aims A novel marker left atrioventricular coupling index (LACI) has been proved to be associated with cardiovascular events in patients without history of cardiovascular disease. However, the studies on cardiac magnetic resonance‐derived LACI in hypertrophic cardiomyopathy (HCM) patients are limited, and the prognostic value of LACI has still ...
Jinyang Wen, Junhao Tu, Xinwei Tao, Yuanyuan Tang, Zhaoxia Yang, Ziyi Pan, Yi Luo, Chunlin Xiang, Dazhong Tang, Lu Huang, Liming Xia   +10 more
wiley   +1 more source

Efficacy and safety of myectomy and radiofrequency septal ablation for treating hypertrophic obstructive cardiomyopathy

Open Heart
Background Novel treatments are needed for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Radiofrequency (RF) septal ablation has emerged as a promising technique for improving the left ventricular outflow tract (LVOT)
Larissa Ventura Ribeiro Bruscky, Bruno Pereira Valdigem, Edileide de Barros Correia, Paulo Chaccur, Andrea de Andrade Vilela, Antônio Tito Paladino Filho, Ibraim Pinto, Rui Fernando Ramos, Jorge Eduardo Assef   +8 more
doaj   +1 more source

A systematic review and pooled analysis of septal myectomy and edge-to-edge mitral valve repair in obstructive hypertrophic cardiomyopathy

Reviews in Cardiovascular Medicine, 2021
Left ventricular outflow tract (LVOT) obstruction and systolic anterior motion (SAM) of the mitral valve (MV) occurs in 70% of hypertrophic cardiomyopathy (HCM) patients.
Christos G. Mihos, Esteban Escolar, Rafle Fernandez, Francesco Nappi   +3 more
doaj   +1 more source

H2FPEF and HFA‐PEFF scores for heart failure risk stratification in hypertrophic cardiomyopathy patients

ESC Heart Failure, EarlyView.
Abstract Aims H2FPEF and HFA‐PEFF scores have demonstrated prognostic value in heart failure (HF) with preserved ejection fraction. This study aimed to explore the value of the H2FPEF and HFA‐PEFF scores for HF risk stratification in patients with hypertrophic cardiomyopathy (HCM).
Yi‐Peng Gao, Hong‐Yun Liu, Xiao‐Jun Bi, Jie Sun, Ying Zhu, Wei Zhou, Ya‐Ting Fan, Xue‐Qing Cheng, Pei‐Na Huang, Ya‐Ni Liu, You‐Bin Deng   +10 more
wiley   +1 more source

Comparing long‐term outcomes of septal myectomy and mitral valve replacement in hypertrophic cardiomyopathy patients: A retrospective cohort study in Iran

Health Science Reports
Background Hypertrophic cardiomyopathy (HCM) affects millions of individuals worldwide. In severe cases, it can cause life‐threatening conditions such as left ventricular outflow tract (LVOT) obstruction, mitral regurgitation (MR), and sudden cardiac ...
Aryan Ayati, Mehran Khoshfetrat, Saeed Davoodi, Seyed Hossein Ahmadi Tafti, Reza Arefizadeh   +4 more
doaj   +1 more source

PlasmaBlade-assisted surgical septal myectomy: technique and our experience

Frontiers in Cardiovascular Medicine
BackgroundThe pulsed-electron avalanche knife (PEAK) PlasmaBlade provides an atraumatic, scalpel-like cutting precision and electrocautery-like hemostasis. PlasmaBlade operates near body temperature, and its long, thin, and malleable tip can overcome the
Pankaj Garg, Amy Lykins, Mohammad Alomari, Jordan P. Reynolds, Elizabeth Johnson, Basar Sareyyupoglu   +5 more
doaj   +1 more source

Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence‐based practice resource of the National Society of Genetic Counselors

Journal of Genetic Counseling, EarlyView.
Abstract Hypertrophic cardiomyopathy (HCM) is a common hereditary condition affecting approximately 1 in 500 adults. It is characterized by marked clinical heterogeneity with individuals experiencing minimal to no symptoms, while others may have more severe outcomes including heart failure and sudden cardiac death.
Erin M. Miller, Emily Brown, Susan Christian, Melissa A. Kelly, Linda M. Knight, Sara Saberi, Christina Rigelsky, Jodie Ingles   +7 more
wiley   +1 more source

Building Disease Detection Algorithms with Very Small Numbers of Positive Samples [PDF]

, 2018
Although deep learning can provide promising results in medical image analysis, the lack of very large annotated datasets confines its full potential. Furthermore, limited positive samples also create unbalanced datasets which limit the true positive rates of trained models.
arxiv   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathy

Cardiovascular Ultrasound, 2022
Background Perfusion defects during stress can occur in hypertrophic cardiomyopathy (HCM) from either structural or functional abnormalities of the coronary microcirculation.
Paola Roldan, Sriram Ravi, James Hodovan, J. Todd Belcik, Stephen B. Heitner, Ahmad Masri, Jonathan R. Lindner   +6 more
doaj   +1 more source